Jason Hsu insider trades: Immix Biopharma (IMMX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jason reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 23, 2024 | IMMX | ↑ Buy | 47,700 | $2.19 | $104K | Direct | Dec 26, 2024 (3d) |
| Aug 22, 2024 | IMMX | ↑ Buy | 23,100 | $2.23 | $52K | Direct | Aug 26, 2024 (4d) |
| Jul 24, 2024 | IMMX | ↑ Buy | 9,200 | $2.12 | $20K | Direct | Jul 31, 2024 (7d) |
| Dec 11, 2023 | IMMX | ↑ Buy | 56,000 | $4.77 | $267K | Direct | Dec 12, 2023 (1d) |
| Sep 15, 2023 | IMMX | ↑ Buy | 72,000 | $2.78 | $200K | Direct | Sep 18, 2023 (3d) |
| Sep 8, 2023 | IMMX | ↑ Buy | 10,000 | $2.53 | $25K | Direct | Sep 12, 2023 (4d) |
| Dec 20, 2021 | IMMX | ↑ Buy | 50,000 | $5.00 | $250K | Indirect | Dec 20, 2021 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IMMX insiders
Open-market trades in the last 12 months
About Jason Hsu's insider trades
Jason Hsu is a director at Immix Biopharma (IMMX). Since Dec 20, 2021, Jason has reported 7 open-market purchases worth $918K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMMX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.